Home The Action MC Substitutes/Other Dr. Tamas Csont (HU)


Dr. Tamas Csont

Scientific Director, Associate Professor
Pharmahungary Group and Cardiovascular Research Group,
Department of Biochemistry,
University of Szeged
Dom ter 9.,
H-6720 Szeged, Hungary

T: +36-62-545755
F: +36-62-545097
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Interests

  • cardiac effects of metabolic diseases (hyperlipidemia, diabetes, uremia)
  • direct myocardial effects of nitroglycerin, influence of vascular nitrate tolerance
  • role of NO, ROS, and peroxynitrite in cardiac pathologies
  • role of miRNAs in cardiac pathologies
  • proteoglycans and cardioprotection

Selected Recent Publications

  •  Varga ZV, Kupai K, Szűcs G, Gáspár R, Pálóczi J, Faragó N, Zvara A, Puskás LG, Rázga Z, Tiszlavicz L, Bencsik P, Görbe A, Csonka C, Ferdinandy P, Csont T. MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart. J Mol Cell Cardiol. 2013 Sep;62:111-21.
  • Fekete V, Murlasits Z, Aypar E, Bencsik P, Sárközy M, Szénási G, Ferdinandy P, Csont T. Myocardial postconditioning is lost in vascular nitrate tolerance. J Cardiovasc Pharmacol. 2013 Sep;62(3):298-303.
  • Sárközy M, Zvara A, Gyémánt N, Fekete V, Kocsis GF, Pipis J, Szűcs G, Csonka C, Puskás LG, Ferdinandy P, Csont T. Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats. Cardiovasc Diabetol. 2013 Jan 15;12:16.
  • Kocsis GF, Sárközy M, Bencsik P, Pipicz M, Varga ZV, Pálóczi J, Csonka C, Ferdinandy P, Csont T. Preconditioning protects the heart in a prolonged uremic condition. Am J Physiol Heart Circ Physiol. 2012 Nov 15;303(10):H1229-36.
  • Csont T, Görbe A, Bereczki E, Szunyog A, Aypar E, Tóth ME, Varga ZV, Csonka C, Fülöp F, Sántha M, Ferdinandy P. Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: role of nitric oxide. J Mol Cell Cardiol. 2010 Apr;48(4):649-52.



POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.